TMLHE Antibody

What is TMLHE and why is it important in metabolic research?

TMLHE (Trimethyllysine Hydroxylase, epsilon) is a mitochondrial enzyme that catalyzes the first step in the carnitine biosynthesis pathway, converting trimethyllysine to hydroxytrimethyllysine. This enzyme plays a crucial role in fatty acid metabolism and energy production by facilitating the synthesis of carnitine, which is essential for transporting long-chain fatty acids into mitochondria for β-oxidation. Dysregulation of TMLHE has been linked to various metabolic disorders and cardiovascular diseases, making it an important target for metabolic research . When designing experiments to study TMLHE function, researchers should consider its subcellular localization (primarily mitochondrial) and tissue-specific expression patterns to optimize detection protocols.

What applications are TMLHE antibodies most commonly used for?

TMLHE antibodies are primarily utilized in several key research applications:

• Western Blotting (WB): For detecting and quantifying TMLHE protein expression in cell or tissue lysates

• ELISA: For quantitative measurement of TMLHE in solution

• Immunohistochemistry (IHC): For visualizing TMLHE expression patterns in tissue sections

• Immunofluorescence (IF): For subcellular localization studies of TMLHE

When designing experiments using TMLHE antibodies, researchers should optimize antibody concentration for each application. Recommended dilutions typically range from 1:50 to 1:100 for immunofluorescence applications . For Western blotting, optimization experiments starting with serial dilutions are advisable to determine the optimal concentration for specific experimental conditions.

How do I select the appropriate TMLHE antibody for my research?

Selecting the appropriate TMLHE antibody depends on several factors:

• Species reactivity: Ensure the antibody reacts with your species of interest. Most TMLHE antibodies are reactive with human samples, but some (like certain polyclonal antibodies) offer broader cross-reactivity across species including rat, mouse, cow, dog, horse, rabbit, chicken, and monkey .

• Application compatibility: Verify that the antibody has been validated for your specific application. Some TMLHE antibodies are validated for multiple applications (WB, ELISA, IHC), while others may be optimized for specific techniques .

• Antibody format: Consider whether you need a conjugated or unconjugated antibody:

  • Unconjugated: For flexible detection strategies

  • FITC-conjugated: For direct fluorescence detection

  • HRP-conjugated: For enzymatic detection systems

  • Biotin-conjugated: For use with streptavidin detection systems

• Epitope recognition: Different antibodies target different regions of the TMLHE protein. Consider whether you need an antibody targeting a specific domain (e.g., N-terminal vs. internal epitopes) .

What are the optimal conditions for using TMLHE antibodies in Western blot experiments?

For optimal Western blot results with TMLHE antibodies, follow these methodological guidelines:

• Sample preparation:

  • Extract proteins from tissues or cells using a mitochondria-enriched fractionation protocol since TMLHE is primarily located in mitochondria

  • Use a lysis buffer containing protease inhibitors to prevent degradation

  • Denature samples at 95°C for 5 minutes in sample buffer containing SDS and a reducing agent

• Protein separation:

  • Load 20-50 μg of total protein per lane

  • Use 10-12% SDS-PAGE gels for optimal resolution of TMLHE (expected molecular weight ~50 kDa)

• Transfer and blocking:

  • Transfer proteins to PVDF membranes (preferred over nitrocellulose for TMLHE)

  • Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Antibody incubation:

  • Dilute primary TMLHE antibody according to manufacturer recommendations (typically 1:500-1:2000)

  • Incubate overnight at 4°C with gentle rocking

  • Wash 3-5 times with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

  • For pre-conjugated HRP TMLHE antibodies, skip the secondary antibody step

• Detection:

  • Use enhanced chemiluminescence (ECL) detection reagents

  • Optimize exposure time to prevent signal saturation

  • Include appropriate positive controls and molecular weight markers

When troubleshooting weak signals, consider extending primary antibody incubation time or increasing antibody concentration. For high background, more stringent washing or increased blocking time may be beneficial.

How can I validate the specificity of a TMLHE antibody?

Validating antibody specificity is critical for reliable research results. For TMLHE antibodies, implement these validation approaches:

• Positive and negative controls:

  • Positive controls: Tissues or cell lines known to express TMLHE (liver, heart, or kidney tissues)

  • Negative controls: Tissues with minimal TMLHE expression or TMLHE knockout/knockdown samples

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunizing peptide (if available)

  • Reduced or absent signal indicates specific binding

• siRNA knockdown validation:

  • Compare TMLHE detection in cells treated with TMLHE-specific siRNA versus control siRNA

  • Significant signal reduction in knockdown samples confirms specificity

• Molecular weight verification:

  • Confirm that the detected band appears at the expected molecular weight (~50 kDa for human TMLHE)

  • Multiple bands may indicate splice variants, post-translational modifications, or non-specific binding

• Cross-platform validation:

  • Compare results across multiple techniques (WB, IHC, IF)

  • Consistent patterns of expression across platforms increase confidence in antibody specificity

Document all validation steps thoroughly in your research protocols and publications to enhance reproducibility.

What are the recommended protocols for immunofluorescence staining with TMLHE antibodies?

For optimal immunofluorescence staining with TMLHE antibodies, follow this detailed protocol:

• Sample preparation:

  • For cultured cells: Grow cells on glass coverslips, fix with 4% paraformaldehyde for 15 minutes at room temperature

  • For tissue sections: Use fresh-frozen or paraffin-embedded sections (4-6 μm thick)

• Permeabilization and blocking:

  • Permeabilize with 0.1-0.3% Triton X-100 in PBS for 10 minutes

  • Block with 5% normal serum (from the same species as the secondary antibody) with 1% BSA in PBS for 1 hour

• Antibody incubation:

  • Dilute TMLHE antibody to 1:50-1:100 in blocking solution

  • Incubate overnight at 4°C in a humidified chamber

  • Wash 3 times with PBS, 5 minutes each

• Secondary antibody:

  • For unconjugated primary antibodies, incubate with fluorophore-conjugated secondary antibody (1:200-1:500) for 1 hour at room temperature

  • For direct detection using FITC-conjugated TMLHE antibodies, skip this step

  • Wash 3 times with PBS, 5 minutes each

• Counterstaining and mounting:

  • Counterstain nuclei with DAPI (1 μg/ml) for 5 minutes

  • Mount with anti-fade mounting medium

  • Seal edges with nail polish for long-term storage

• Mitochondrial co-localization:

  • Consider double-staining with mitochondrial markers (e.g., MitoTracker or antibodies against other mitochondrial proteins) to confirm the subcellular localization of TMLHE

  • Use confocal microscopy for optimal resolution of mitochondrial structures

Optimize the protocol for your specific cell type or tissue by adjusting fixation conditions, permeabilization strength, and antibody concentration.

How can I use TMLHE antibodies to investigate carnitine biosynthesis pathway defects?

Investigating carnitine biosynthesis pathway defects using TMLHE antibodies requires a multi-faceted approach:

• Expression analysis in disease models:

  • Compare TMLHE protein levels between normal and disease samples using quantitative Western blotting

  • Perform immunohistochemistry to analyze tissue-specific changes in TMLHE expression patterns

  • Use flow cytometry with permeabilized cells to quantify TMLHE levels in specific cell populations

• Functional assays:

  • Combine TMLHE antibody-based detection with enzymatic activity assays to correlate protein levels with functional output

  • Measure trimethyllysine and hydroxytrimethyllysine levels using mass spectrometry in parallel with TMLHE protein quantification

  • Assess mitochondrial function parameters (oxygen consumption, ATP production) in relation to TMLHE expression

• Interaction studies:

  • Use co-immunoprecipitation with TMLHE antibodies to identify protein-protein interactions within the carnitine biosynthesis pathway

  • Perform proximity ligation assays to visualize TMLHE interactions with other pathway components in situ

  • Analyze post-translational modifications of TMLHE that might regulate its activity

• Genetic correlation studies:

  • Combine TMLHE protein quantification with genetic analysis of TMLHE mutations

  • Correlate specific mutations with altered protein expression, localization, or stability

  • Develop assays to distinguish between primary TMLHE defects and secondary dysregulation

This integrated approach provides a comprehensive understanding of how TMLHE dysfunction contributes to carnitine biosynthesis pathway defects and associated metabolic disorders.

What are the key considerations when using TMLHE antibodies for quantitative analysis?

For accurate quantitative analysis using TMLHE antibodies, researchers should address these critical considerations:

• Antibody validation for quantitative applications:

  • Verify linear dynamic range of antibody detection

  • Determine limit of detection and quantification

  • Test batch-to-batch reproducibility

• Sample standardization:

  • Normalize TMLHE levels to appropriate loading controls (β-actin for whole-cell lysates, VDAC or COX IV for mitochondrial fractions)

  • Include calibration standards when possible

  • Process all experimental samples simultaneously to minimize technical variation

• Quantification methods:

  • For Western blots: Use digital imaging with appropriate software for densitometric analysis

  • For ELISA: Generate standard curves using recombinant TMLHE protein

  • For immunofluorescence: Apply consistent image acquisition parameters and quantify signal intensity with specialized software

• Statistical analysis:

  • Account for biological and technical replicates

  • Apply appropriate statistical tests based on data distribution

  • Consider power analysis to determine adequate sample size

• Reporting standards:

  • Document all quantification methods in detail

  • Report raw data alongside normalized values

  • Include measures of variability (standard deviation, standard error)

Following these guidelines ensures that quantitative data generated using TMLHE antibodies is reliable, reproducible, and biologically meaningful.

How can I optimize immunoprecipitation protocols for TMLHE protein complexes?

Optimizing immunoprecipitation (IP) of TMLHE protein complexes requires careful consideration of several parameters:

• Lysis buffer optimization:

  • Use mitochondria-specific lysis buffers containing 0.5-1% non-ionic detergents (e.g., NP-40, Triton X-100)

  • Include protease inhibitors, phosphatase inhibitors, and reducing agents

  • Test different salt concentrations (150-300 mM NaCl) to balance complex stability and background binding

• Antibody selection and coupling:

  • Choose highly specific TMLHE antibodies validated for IP applications

  • Consider using protein A/G magnetic beads for efficient capture

  • For increased specificity, directly couple purified antibodies to activated beads

• Pre-clearing and blocking steps:

  • Pre-clear lysates with protein A/G beads without antibody

  • Block beads with BSA or non-immune IgG before adding antibody

  • Include isotype control antibodies as negative controls

• Incubation conditions:

  • Optimize antibody-to-lysate ratio

  • Test different incubation times (2 hours to overnight)

  • Perform IP at 4°C with gentle rotation to preserve complex integrity

• Washing stringency:

  • Develop a multi-step washing protocol with decreasing salt concentrations

  • Monitor complex stability versus background reduction

  • Consider detergent concentration in wash buffers

• Elution and analysis:

  • Compare different elution methods (pH, SDS, peptide competition)

  • For downstream mass spectrometry, avoid detergents incompatible with MS

  • Consider native elution conditions for functional studies of isolated complexes

Additional considerations for studying TMLHE complexes include performing crosslinking prior to lysis to stabilize transient interactions and using proximity labeling approaches (BioID, APEX) to identify interaction partners in their native cellular context.

How does TMLHE function in normal cellular metabolism?

TMLHE (Trimethyllysine Hydroxylase, epsilon) plays a fundamental role in cellular metabolism through these key functions:

• Carnitine biosynthesis pathway:

  • TMLHE catalyzes the first step in carnitine biosynthesis, converting trimethyllysine (TML) to 3-hydroxy-TML

  • This hydroxylation reaction requires molecular oxygen, Fe²⁺, and 2-oxoglutarate as cofactors

  • The reaction is a rate-limiting step in the four-step pathway that ultimately produces carnitine

• Role in fatty acid metabolism:

  • By supporting carnitine production, TMLHE indirectly facilitates transport of long-chain fatty acids into mitochondria

  • This process is essential for β-oxidation and energy production from fatty acids

  • TMLHE activity modulates cellular capacity for lipid metabolism

• Mitochondrial function:

  • TMLHE is primarily localized to the mitochondrial matrix

  • Its activity influences mitochondrial bioenergetics through its effects on fatty acid availability

  • TMLHE may participate in protein-protein interactions with other mitochondrial enzymes to coordinate metabolic pathways

• Tissue-specific expression and function:

  • TMLHE is most highly expressed in tissues with high energy demands (heart, skeletal muscle, liver)

  • Expression patterns suggest tissue-specific roles in regulating fatty acid metabolism

  • Regulatory mechanisms controlling TMLHE expression remain an active area of research

Understanding these fundamental aspects of TMLHE biology provides the foundation for investigating its role in pathological conditions.

What is the evidence linking TMLHE dysfunction to metabolic disorders and cardiovascular diseases?

The association between TMLHE dysfunction and various pathological conditions is supported by multiple lines of evidence:

• Metabolic disorders:

  • Studies have identified altered TMLHE expression in tissues from patients with metabolic syndrome

  • TMLHE gene variants show statistical associations with altered lipid profiles

  • Animal models with reduced TMLHE activity exhibit impaired fatty acid oxidation and insulin resistance

  • Liver-specific TMLHE deficiency leads to hepatic steatosis in experimental models

• Cardiovascular diseases:

  • TMLHE expression is altered in cardiac tissues from heart failure patients

  • Carnitine deficiency resulting from impaired TMLHE function is associated with cardiomyopathy

  • Reduced TMLHE activity correlates with decreased cardiac energetic capacity

  • TMLHE polymorphisms have been identified as potential risk factors for certain cardiovascular conditions

• Neurological conditions:

  • TMLHE deficiency has been linked to neurodevelopmental disorders

  • Brain-specific alterations in carnitine metabolism may contribute to neurological manifestations

  • Studies suggest potential roles in neuroprotection against oxidative stress

• Molecular mechanisms:

  • TMLHE dysfunction leads to reduced carnitine availability

  • This results in impaired long-chain fatty acid transport into mitochondria

  • Consequent accumulation of fatty acids in the cytosol triggers lipotoxicity

  • Altered energy metabolism contributes to cellular dysfunction and tissue damage

These findings highlight the importance of TMLHE in maintaining metabolic homeostasis and suggest its potential as a therapeutic target for metabolic and cardiovascular diseases.

How can TMLHE antibodies be used in drug discovery and development for metabolic diseases?

TMLHE antibodies serve as valuable tools in the drug discovery and development pipeline for metabolic diseases through several applications:

• Target validation:

  • Confirm TMLHE expression in disease-relevant tissues

  • Quantify alterations in TMLHE levels in disease states

  • Correlate TMLHE expression with disease progression markers

  • Validate effects of genetic manipulation (knockout, knockdown, overexpression) on metabolic parameters

• High-throughput screening:

  • Develop cell-based immunoassays to screen compounds that modulate TMLHE expression or activity

  • Establish antibody-based competition assays to identify molecules binding to TMLHE

  • Create reporter systems using TMLHE antibodies for real-time monitoring of drug effects

• Mechanism of action studies:

  • Investigate how lead compounds affect TMLHE expression, localization, or post-translational modifications

  • Use immunoprecipitation with TMLHE antibodies to identify drug-induced changes in protein-protein interactions

  • Combine with activity assays to correlate drug effects on protein levels with functional outcomes

• Biomarker development:

  • Assess TMLHE protein levels as potential biomarkers for disease diagnosis or treatment response

  • Develop sensitive immunoassays for detecting TMLHE in accessible biological samples

  • Correlate changes in TMLHE with clinical outcomes in treatment studies

• Advanced drug development:

  • Monitor on-target and off-target effects of TMLHE-modulating compounds

  • Develop companion diagnostics using TMLHE antibodies

  • Establish pharmacodynamic markers based on TMLHE expression or activity

These applications demonstrate how TMLHE antibodies contribute to the rational design and development of therapeutics targeting metabolic pathways related to carnitine biosynthesis.

What are common pitfalls when working with TMLHE antibodies and how can they be addressed?

Researchers frequently encounter these challenges when working with TMLHE antibodies, along with recommended solutions:

• Non-specific binding:

  • Problem: Multiple bands in Western blots or diffuse staining in IHC/IF

  • Solutions:

    • Increase blocking time and concentration

    • Optimize antibody dilution through titration experiments

    • Include competing peptides to confirm specificity

    • Use more stringent washing conditions

    • Consider alternative antibody clones targeting different epitopes

• Weak or absent signal:

  • Problem: Unable to detect TMLHE despite expected expression

  • Solutions:

    • Verify sample preparation preserves mitochondrial proteins

    • Optimize protein extraction methods for mitochondrial proteins

    • Increase antibody concentration or incubation time

    • Enhance signal using amplification systems

    • Verify antibody storage conditions to prevent degradation

• Inconsistent results:

  • Problem: Variable outcomes between experiments

  • Solutions:

    • Standardize all protocol steps and reagent concentrations

    • Use positive controls with known TMLHE expression

    • Implement quantitative controls (recombinant proteins)

    • Document lot numbers and storage conditions of antibodies

    • Consider antibody validation with orthogonal methods

• Background in immunofluorescence:

  • Problem: High non-specific fluorescence obscuring specific signal

  • Solutions:

    • Optimize fixation conditions (duration, temperature)

    • Test alternative permeabilization methods

    • Use directly conjugated antibodies to eliminate secondary antibody background

    • Include appropriate controls for autofluorescence

    • Apply confocal microscopy for improved signal-to-noise ratio

Maintaining detailed laboratory records of optimization experiments helps establish reliable protocols and facilitates troubleshooting when unexpected results occur.

How should TMLHE antibodies be properly stored and handled to maintain optimal performance?

Proper storage and handling are critical for maintaining antibody performance over time:

• Storage conditions:

  • Store unconjugated TMLHE antibodies at -20°C for long-term storage

  • Store conjugated antibodies (FITC, HRP, biotin) at 4°C protected from light

  • Avoid repeated freeze-thaw cycles by preparing small working aliquots

  • Monitor storage temperature with calibrated thermometers

• Working solution preparation:

  • Thaw antibodies slowly on ice or at 4°C

  • Centrifuge briefly before opening to collect liquid at the bottom

  • Prepare fresh working dilutions for each experiment

  • Use sterile buffers with preservatives for diluted antibodies

• Stability considerations:

  • Unconjugated antibodies typically remain stable for 12-24 months when properly stored

  • Conjugated antibodies have shorter shelf lives (6-12 months)

  • Monitor expiration dates and perform regular quality control tests

  • Observe solutions for signs of contamination or precipitation

• Transportation and temporary storage:

  • Transport on ice or with cold packs

  • Minimize exposure to room temperature

  • Protect from direct light, especially fluorophore-conjugated antibodies

  • Return to proper storage conditions promptly after use

• Documentation practices:

  • Record receipt date, lot number, and initial validation results

  • Document each use, including freeze-thaw cycles

  • Maintain performance records to identify degradation over time

  • Implement regular validation testing for antibodies in long-term storage

Following these guidelines ensures maximum antibody performance and experimental reproducibility while extending the useful life of valuable research reagents.

How can I compare the performance of different TMLHE antibodies for my specific research application?

Systematic comparison of different TMLHE antibodies requires a methodical approach:

• Initial characterization:

  • Compile information on each antibody's specifications (host, clonality, immunogen, epitope)

  • Review available validation data from manufacturers

  • Note detection limits and recommended applications

  • Document lot-to-lot consistency information if available

• Side-by-side comparison protocol:

  • Test all antibodies simultaneously using identical samples

  • Include positive controls (tissues/cells with known TMLHE expression)

  • Include negative controls (tissues/cells with minimal TMLHE expression)

  • Process all samples under identical conditions

• Application-specific evaluation criteria:

  • For Western blotting:

    • Compare signal-to-noise ratio at equivalent dilutions

    • Assess specificity (single band vs. multiple bands)

    • Evaluate sensitivity (minimum detectable amount)

    • Test linearity across a range of protein concentrations

  • For immunohistochemistry/immunofluorescence:

    • Compare staining intensity and pattern specificity

    • Evaluate background staining levels

    • Assess consistency across different fixation methods

    • Test co-localization with mitochondrial markers

  • For ELISA/immunoassays:

    • Generate standard curves for each antibody

    • Compare dynamic range and sensitivity

    • Evaluate coefficient of variation across replicates

    • Test recovery of known amounts of recombinant protein

• Systematic performance scoring:

  • Develop a quantitative scoring system for each criterion

  • Weight criteria according to importance for your specific application

  • Calculate composite performance scores

  • Document results in a comparative table

This standardized approach enables objective selection of the optimal TMLHE antibody for specific research applications while documenting the decision-making process for future reference.

How are TMLHE antibodies being used in single-cell analysis techniques?

TMLHE antibodies are being integrated into cutting-edge single-cell analysis platforms through several innovative approaches:

• Single-cell immunofluorescence:

  • TMLHE antibodies combined with high-content imaging systems enable quantification of protein expression at the single-cell level

  • Automated image analysis algorithms can identify subpopulations based on TMLHE expression patterns

  • Co-staining with cell type-specific markers allows correlation of TMLHE levels with cellular identity

  • Live-cell imaging with membrane-permeable fluorescent TMLHE antibodies can track dynamic changes in expression

• Mass cytometry (CyTOF):

  • Metal-conjugated TMLHE antibodies enable detection in mass cytometry panels

  • Simultaneous measurement of TMLHE with dozens of other proteins at single-cell resolution

  • Hierarchical clustering and dimensionality reduction techniques reveal relationships between TMLHE expression and cellular phenotypes

  • Integration with signaling markers provides insights into TMLHE regulation

• Spatial transcriptomics integration:

  • Combining TMLHE antibody staining with spatial transcriptomics approaches

  • Correlation of protein levels with mRNA expression in intact tissue sections

  • Analysis of spatial relationships between TMLHE-expressing cells and microenvironmental features

  • Development of computational methods to integrate protein and RNA data

• Microfluidic applications:

  • Antibody-based capture of TMLHE-expressing cells in microfluidic devices

  • Single-cell Western blotting for quantitative analysis of TMLHE in individual cells

  • Droplet-based assays for high-throughput screening of TMLHE modulators at the single-cell level

  • Integration with metabolic profiling to correlate TMLHE expression with functional outputs

These emerging applications represent the frontier of TMLHE research, offering unprecedented resolution to study its role in cellular heterogeneity and metabolic regulation.

What are the latest developments in using machine learning and computational approaches with TMLHE antibody data?

Advanced computational approaches are transforming how researchers analyze and interpret TMLHE antibody data:

• Deep learning for image analysis:

  • Convolutional neural networks trained to recognize TMLHE staining patterns in IHC/IF images

  • Automated quantification of expression levels across large tissue datasets

  • Identification of subtle expression patterns undetectable by conventional analysis

  • Integration of TMLHE localization with morphological features

• Predictive modeling for antibody selection:

  • Machine learning algorithms trained on antibody performance metrics

  • Development of prediction tools for epitope accessibility and antibody specificity

  • Computational methods to optimize antibody-antigen binding

  • In silico prediction of cross-reactivity and potential artifacts

• Systems biology integration:

  • Network analysis incorporating TMLHE protein interaction data

  • Multi-omics data integration (proteomics, metabolomics, transcriptomics)

  • Bayesian approaches to infer causal relationships between TMLHE and downstream effectors

  • Pathway modeling to predict effects of TMLHE modulation

• Digital pathology applications:

  • Whole-slide image analysis of TMLHE immunohistochemistry

  • Patient stratification based on TMLHE expression patterns

  • Correlation of expression with clinical outcomes

  • Development of computer-aided diagnostic tools incorporating TMLHE status

• Antibody design optimization:

  • Computational methods for designing improved TMLHE antibodies

  • Structure-based epitope prediction and optimization

  • Generative adversarial networks to design antibody sequences with enhanced specificity and affinity

  • In silico validation of antibody performance before experimental testing

These computational approaches are accelerating research by enabling more sophisticated analysis of TMLHE antibody data and facilitating the design of next-generation reagents with enhanced performance characteristics.

How can TMLHE antibodies contribute to research on mitochondrial dynamics and quality control?

TMLHE antibodies provide valuable tools for investigating the relationship between carnitine metabolism and mitochondrial quality control:

• Mitochondrial morphology and distribution:

  • Co-labeling with TMLHE antibodies and mitochondrial markers reveals relationships between carnitine metabolism and mitochondrial network organization

  • Time-lapse imaging with TMLHE antibodies can track changes in enzyme distribution during mitochondrial fission/fusion events

  • Quantitative analysis of TMLHE localization patterns during mitochondrial stress responses

  • High-resolution microscopy (STED, STORM) with TMLHE antibodies enables nanoscale analysis of submitochondrial localization

• Mitophagy and mitochondrial turnover:

  • Monitoring TMLHE levels during induced mitophagy

  • Co-localization studies with autophagy markers to track TMLHE-containing mitochondria during selective degradation

  • Analysis of TMLHE as a potential regulator of mitochondrial turnover

  • Correlation between TMLHE activity and mitochondrial quality control efficiency

• Mitochondrial biogenesis:

  • Tracking TMLHE expression during mitochondrial biogenesis

  • Investigating coordination between TMLHE synthesis and import with other mitochondrial proteins

  • Analysis of TMLHE as a potential biomarker for mitochondrial content and functionality

  • Studying regulatory relationships between TMLHE and master regulators of mitochondrial biogenesis

• Stress responses and adaptation:

  • Monitoring TMLHE expression and localization during metabolic stress

  • Investigating the role of TMLHE in mitochondrial adaptation to nutrient availability

  • Analyzing TMLHE post-translational modifications in response to mitochondrial stress

  • Studying the relationship between TMLHE activity and mitochondrial membrane potential maintenance

These research directions highlight how TMLHE antibodies contribute to our understanding of the intricate relationship between carnitine metabolism and fundamental aspects of mitochondrial biology, potentially revealing new therapeutic targets for mitochondrial dysfunction.